Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Investigator Meeting for New NETT Hubs November 12, 2012 NIH-NINDS U01 NSO69498.

Slides:



Advertisements
Similar presentations
Patient Recruitment Patient Recruitment Thomas Devlin, MD PhD Erlanger Southeast Regional Stroke Center.
Advertisements

Managing Sick Days and Hospital Stays Mike Heile MD Orlando, CWD July, 2011.
Stroke Care is a Team Sport
Adverse Events and Serious Adverse Events
GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.
In-Patient Management of Hyperglycemia Rey Vivo, MD Assistant Professor of Medicine Texas Tech University Health Sciences Center.
A Guide to Diabetes in the School Setting © McKinney Independent School District.
Introducing The SHINE Trial (Stroke Hyperglycemia Insulin Network Effort) An Overview for Clinical Nurses NIH-NINDS U01 NSO69498.
Introducing: The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Karen C. Johnston Amy C. Fansler For the SHINE team NIH-NINDS U01 NS NETT.
TPA… SMART or not SMART? That is the Question. Sarah Parker, MD.
Hyperacute Stroke Treatment: Inclusion and Exclusion Criteria
Modified Megestrol The Clinical Trials by : Carolina R. Akib
Consent for Research Study A study for patients newly diagnosed with advanced glioblastoma (brain cancer): Learning whether a PET scan with F-fluoromisonidazole.
RPI AMBULANCE. Topics to Cover Indications for Blood Glucose testing Symptoms/Differences of Hypoglycemia and Hyperglycemia Treatment for hypoglycemia.
Screening and Eligibility for DPP Clinical Guidelines.
…in an academic collaboration with ISRCTN
What can we do to cut down the time it takes to give a clot dissolving drug (tPA)?
Systems in Acute Stroke Care Andy Jagoda, MD Professor of Emergency Medicine Department of Emergency Medicine Mount Sinai School of Medicine New York,
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Preparing Study Orders & Laptops Amy Fansler SHINE Project Director.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial I-SPOT Nina Gentile, MD Hannah Reimer.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Protocol Cases and Q&A Karen C. Johnston, MD, MSc Administrative PI.
Stroke Quality Measures Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed: May, 2012 Most recently updated: October,
DIABETES Power over Diabetes Presented by: Regina Weitzman, MD.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.
Diabetes in the School Setting Mission Consolidated Independent School District Health Services Ph:
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Intervention Studies Principles of Epidemiology Lecture 10 Dona Schneider, PhD, MPH, FACE.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial NIH-NINDS U01 NS An Overview of SHINE.
Management of Inpatient Blood Glucose at Temple Housestaff Orientation 2014.
What is Diabetes? Diabetes is a disease that prevents the body from properly using the energy from the food you eat.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols Askiel Bruno, MD, MS Protocol PI.
Module 3 Initial Recognition, Triaging, and Management of Hyperglycemia Diabetes Special Interest Group Georgia Hospital Association.
Beth Sassano CPC, CCS-P, CPMA, CPC-I Diabetes. Diabetes mellitus (DM) is a syndrome characterized by hyperglycemia from impaired insulin production. Associated.
Skills Training Session February 11, Agenda Quiz Run report guidelines, feedback Scenario Debrief Diabetic Emergencies.
The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Brief Protocol Training NIH-NINDS U01 NS NETT CCC U01 NS NETT SDMC U01 NS
Introducing the SHINE Trial An Overview Karen C. Johnston, MD, MSc Administrative PI.
Diabetes in the School Setting Level I Training. IDEA - Public Law Student Rights All students are entitled to: –Free and appropriate public education.
Internet-based pilot study comparing low fat with high fat evening snacks in children and adolescents with Type 1 Diabetes using continuous glucose monitoring.
Consent for Research Study A study for patients diagnosed with locally advanced breast cancer Learning if the imaging agent, [ 18 F] fluorothymidine (FLT),
CHP400: Community Health Program - lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Present: Disease Past: Exposure Cross - section.
A1c Testing Team G, Chart Review SAMUEL LAI 1/2015.
Managing Diabetes in the School Setting Alabama State Department of Education Alabama Board of Nursing.
Arthi Ramakrishnan SHINE Site Manager Stroke Hyperglycemia Insulin Network Effort (SHINE) Stroke Hyperglycemia Insulin Network Effort (SHINE) Regulatory.
Consent for Research Study A study for patients newly diagnosed with advanced glioblastoma (brain cancer): Learning whether a PET scan with F-fluoromisonidazole.
Managing Diabetes in the School Setting Alabama State Department of Education Alabama Board of Nursing.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Site Monitoring Shirley Frederiksen Donna Harsh.
Investigational Devices and Humanitarian Use Devices June 2007.
Diabetes Mellitus Ch 13 ~ Endocrine System Med Term.
Sanaz Sakiani, MD Endocrinology Fellow Journal Club
Special Situations In The Management Of In-Patient Hyperglycemia
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocol Cases.
What is Diabetes? Definition: A disorder of metabolism where the pancreas produces little or no insulin or the cells do not respond to the insulin produced.
Adult Stroke 2010 AHA Guidelines for CPR and ECC
and Altered Mental Status
For Employees of the Randolph County School System
HOW TO SCREEN PATIENTS AND BOOK THE BASELINE VISIT APPOINTMENT?
PRCSG Training Webinar: Budget for Industry Sponsored Studies
EndoTool IV Physician User Guide Content Expert:
بايو كمستري (م 3) / د . احمد الطويل
Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.
GLUCOSE TOLERANCE TEST (GTT)
What is Diabetes Type 1 The more severe form of diabetes is type 1, or insulin-dependent diabetes. It’s sometimes called “juvenile” diabetes, because.
ESETT Eligibility Overview
ARCADIA Coordinator Webinar
SCREENING AND MANAGEMENT OF ASYMPTOMATIC NEWBORNS
The Time Dependence of Anti-thrombin Initiation in Patients with Non-ST-segment –elevation Acute Coronary Syndrome: Subgroup Analysis form the ACUITY.
Managing Diabetes in the School Setting
Extended Window Thrombectomy
Managing Diabetes in the School Setting
MANDATORY INSULIN EDUCATION
Presentation transcript:

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Investigator Meeting for New NETT Hubs November 12, 2012 NIH-NINDS U01 NSO69498

Stroke Hyperglycemia Insulin Network Effort Investigator Meeting Agenda 7:00-8:00am BREAKFAST/REGISTRATION 8:00-8:15Opening Remarks - Barsan/Janis/Johnston 8:15-8:45Eligibility - Johnston 8:45-10:15Protocol Training - Bruno Review of the basics Hypoglycemia protocols & pauses Post protocol & outcomes - Johnston 10:15-10:45BREAK 10:45-11:45Study Laptop Training - Zito 11:45-12:30pmProtocol Cases and Q&A - Johnston 12:30-1:30LUNCH 1:30-2:00Randomization and Navigating in WebDCU - Briggs 2:00-2:45Preparing for Site Readiness Preparing study orders & laptops - Fansler Regulatory requirements & RC process - Ramakrishnan Coordinator panel from enrolling sites - Ewing/Fansler/Hall/Reimer 2:45-3:00Safety Reporting - Dillon 3:00-3:15Monitoring - Frederiksen/Harsh 3:15-3:30BREAK 3:30-3:45Recruitment Update - Hall 3:45-4:15I-SPOT - Gentile/Reimer 4:15Adjourn

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Eligibility Karen C. Johnston, MD, MSc Administrative PI

Inclusion Criteria Age 18 years or older Diagnosis of ischemic stroke (neuroimaging must exclude ICH) Treatment must begin w/in 12 hrs of stroke symptom onset and w/in 3 hrs of hospital arrival (protocol change underway, request variation)

Inclusion Criteria Known Type II DM & glucose >110 mg/dL OR blood glucose ≥150 mg/dL in pts w/o known diabetes ( finger stick at enrolling hospital ) Baseline NIHSS 3-22 ( within 30 min of randomization ) Pre-stroke mRS of 0 ( protocol change underway ) Valid informed consent

Exclusion Criteria Type I DM ( hx, records, docs, etc ) Neurological or psychiatric illness that would confound neurological or outcome assessment ( Exclude any pt deemed by enrolling physician to have condition that confounds enrollment neurological exam ) Received experimental therapy for enrollment stroke. (IV tPA (up to 4.5 hrs), IA tPA &IA therapies including FDA cleared devices allowed. Non FDA cleared devices excluded)

Exclusion Criteria Pregnant or breast-feeding Other serious conditions that make pt unlikely to survive 90 days Inability to follow protocol or return for 90 day f/u Renal dialysis

Common Eligibility Questions

Q1: How do we distinguish between Type 1 and Type 2 diabetes when we are trying to determine if a patient meets eligibility criteria to be enrolled?

A1: T1DM vs T2DM Based on history provided by patient/family and medical records or physician contact Any pt on insulin therapy with no known history of oral agents assumed to be T1 Ask the following questions – Ever tried to control diabetes with diet/exercise only? – Ever taken a pill for your diabetes? – Since diagnosis always used insulin (shots or pump)? – Age when diagnosed? Contact the PI on call with questions

T1DM vs T2DM (FAQ info) Type 1 (also called T1DM, insulin-dependent or juvenile diabetes) Commonly is diagnosed from infancy to the late 30s Pancreas produces little or no insulin Cannot be prevented and no cure Causes dependence on injected or pumped insulin for life Type 2 (also called T2DM, non-insulin-dependent or adult-onset diabetes) Most common form of diabetes Typically develops after age 40, but can appear earlier Body does not produce enough or use insulin effectively Treatments include diet, exercise, oral medications or insulin.

Q2: What do we do when a patient says he has borderline diabetes?

A2: Borderline Diabetes Must either have a history of type 2 diabetes and a glucose level of >110mg/dL OR a glucose level of >150mg/dL with no known history of diabetes. Diagnosis of diabetes based medical history provided by the pt/family and/or the medical record. If a pt/family reports a history of borderline diabetes and it is not clear in the medical record, contact the PI on call.

Q3: A potential subject is known to be a type 2 diabetic and is insulin dependent at home. Can we enroll someone who on NPH insulin?

A3: Enrolling Insulin Dependent Diabetic Many diabetics will be on home insulin and are eligible Special situation – on insulin pump – not an exclusion but up to the discretion of enrolling investigator All home DM meds will be held during study treatment

Q4: Can we use the glucose check from the EMS for eligibility?

A4: Eligibility Glucose Check No – cannot use OSH or EMS POC result Need one POC glucose check (finger stick) at enrolling hospital prior to randomization Cannot be a serum glucose level from lab Once you have an eligible POC result, you do not have to repeat before randomization If another check is done and not in range, pt no longer eligible and should not be randomized If BG is below the eligible level but close, you may check again later

Q5: We are screening an 81 y/o man with diabetes who has had a stroke with right sided ataxia. The ataxia completely resolved. He has numbness in both his feet. He lives alone and walks with a cane. How do we score the pre-stroke mRS?

Has the patient had a previous stroke? If yes, have all symptoms from previous stroke resolved? Is the patient able to walk without assistance and live independently? If no previous stroke, continue. If no, patient is not eligible. If yes, continue. If no, patient is not eligible. If yes, pre- stroke mRS=0. The pre-stroke mRS & eligibility

A5: Pre-stroke mRS mRS = 0 – Stroke symptoms have resolved – His numbness is his diabetic neuropathy – He is independent – A cane is a necessary device for walking and is not considered assistance Sample mRS cases posted on study website – May be helpful in training investigators

Q6: Should we enroll a patient with a POC glucose of 451mg/dL in the ED if he meets all of the other eligibility criteria?

A6: Screening a Patient w/ High Glucose Should not enroll if pt requires insulin infusion (DKA, hyperosmolar coma, etc) Any SHINE patient with BG> 500 requires notification of the safety monitor and may be withdrawn from study treatment Enrollment of pts with very high glucose is per judgment of investigator/treating team